scholarly journals Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma

Neoplasia ◽  
2021 ◽  
Vol 23 (9) ◽  
pp. 859-869
Author(s):  
Kajsa E. Affolter ◽  
Sabine Hellwig ◽  
David A. Nix ◽  
Mary P. Bronner ◽  
Alun Thomas ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Prognostic Biomarker ◽  
Circulating Tumor Dna ◽  
Ductal Adenocarcinoma ◽  
Next Generation ◽  
Tumor Dna ◽  
Generation Sequencing

scholarly journals Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer

2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Hitendra Patel ◽  
Ryosuke Okamura ◽  
Paul Fanta ◽  
Charmi Patel ◽  
Richard B. Lanman ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Prognostic Factor ◽  
Median Number ◽  
Circulating Tumor Dna ◽  
Ductal Adenocarcinoma ◽  
Next Generation ◽  
Poor Prognostic Factor ◽  
Resectable Disease ◽  
Tumor Dna ◽  
Generation Sequencing

Abstract Background Treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain dismal. There are unmet needs for understanding the biologic basis of this malignancy using novel next-generation sequencing technologies. Herein, we investigated the clinical utility of circulating tumor DNA (ctDNA) (the liquid biopsy) in this malignancy. Methods ctDNA was analyzed in 112 patients with PDAC (54–73 genes) and tissue DNA in 66 patients (315 genes) (both clinical-grade next-generation sequencing). Number of alterations, %ctDNA, concordance between ctDNA and tissue DNA, and correlation of ctDNA results with survival were assessed. Results The most common genes altered in ctDNA were TP53 (46% of patients, N = 51) and KRAS (44%, N = 49). Median number of characterized ctDNA alterations per patient was 1 (range, 0–6), but patients with advanced PDAC had significantly higher numbers of ctDNA alterations than those with surgically resectable disease (median, 2 versus 0.5, P = 0.04). Overall, 75% (70/94) of advanced tumors had ≥ 1 ctDNA alteration. Concordance rate between ctDNA and tissue DNA alterations was 61% for TP53 and 52% for KRAS. Concordance for KRAS alterations between ctDNA and tissue DNA from metastatic sites was significantly higher than between ctDNA and primary tumor DNA (72% vs 39%, P = 0.01). Importantly, higher levels of total %ctDNA were an independent prognostic factor for worse survival (hazard ratio, 4.35; 95% confidence interval, 1.85–10.24 [multivariate, P = 0.001]). A patient with three ctDNA alterations affecting the MEK pathway (GNAS, KRAS, and NF1) attained a response to trametinib monotherapy ongoing at 6 months. Conclusions Our findings showed that ctDNA often harbored unique alterations some of which may be targetable and that significantly greater numbers of ctDNA alterations occur in advanced versus resectable disease. Furthermore, higher ctDNA levels were a poor prognostic factor for survival.

scholarly journals Panel of serum miRNAs as potential non-invasive biomarkers for pancreatic ductal adenocarcinoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Imteyaz Ahmad Khan ◽  
Safoora Rashid ◽  
Nidhi Singh ◽  
Sumaira Rashid ◽  
Vishwajeet Singh ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Early Stage ◽  
Ductal Adenocarcinoma ◽  
Next Generation ◽  
Serum Samples ◽  
Tissue Samples ◽  
Non Invasive ◽  
Specific Symptoms ◽  
Generation Sequencing

AbstractEarly-stage diagnosis of pancreatic ductal adenocarcinoma (PDAC) is difficult due to non-specific symptoms. Circulating miRNAs in body fluids have been emerging as potential non-invasive biomarkers for diagnosis of many cancers. Thus, this study aimed to assess a panel of miRNAs for their ability to differentiate PDAC from chronic pancreatitis (CP), a benign inflammatory condition of the pancreas. Next-generation sequencing was performed to identify miRNAs present in 60 FFPE tissue samples (27 PDAC, 23 CP and 10 normal pancreatic tissues). Four up-regulated miRNAs (miR-215-5p, miR-122-5p, miR-192-5p, and miR-181a-2-3p) and four down-regulated miRNAs (miR-30b-5p, miR-216b-5p, miR-320b, and miR-214-5p) in PDAC compared to CP were selected based on next-generation sequencing results. The levels of these 8 differentially expressed miRNAs were measured by qRT-PCR in 125 serum samples (50 PDAC, 50 CP, and 25 healthy controls (HC)). The results showed significant upregulation of miR-215-5p, miR-122-5p, and miR-192-5p in PDAC serum samples. In contrast, levels of miR-30b-5p and miR-320b were significantly lower in PDAC as compared to CP and HC. ROC analysis showed that these 5 miRNAs can distinguish PDAC from both CP and HC. Hence, this panel can serve as a non-invasive biomarker for the early detection of PDAC.

Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA

2021 ◽  
pp. 104685
Author(s):  
Regina Stitz ◽  
Anna Buder ◽  
Rene Silye ◽  
Bernhard Baumgartner ◽  
Franz Pühringer ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Circulating Tumor Dna ◽  
Egfr Mutations ◽  
Next Generation ◽  
Tumor Dna ◽  
Generation Sequencing

Anchored Multiplex PCR Enables Sensitive and Specific Detection of Variants in Circulating Tumor DNA by Next-Generation Sequencing

2017 ◽  
Vol 214-215 ◽  
pp. 47 ◽  
Author(s):  
Jerome Lee ◽  
Namitha Manoj ◽  
Josh Haimes ◽  
Skyler Mishkin ◽  
Laura Griffin ◽  
...  
Keyword(s):  
Next Generation Sequencing ◽  
Multiplex Pcr ◽  
Circulating Tumor Dna ◽  
Next Generation ◽  
Specific Detection ◽  
Tumor Dna ◽  
Generation Sequencing
Sign in / Sign up

Export Citation Format

Share Document